Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel
NASDAQ:PRCT

PROCEPT BioRobotics Q3 2026 Earnings Date & Estimates

PROCEPT BioRobotics logo
$17.90 -0.01 (-0.06%)
Closing price 10/8/2026 04:00 PM Eastern
Extended Trading
$17.96 +0.06 (+0.34%)
As of 07:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PROCEPT BioRobotics is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from PROCEPT BioRobotics in Q3 2026

PROCEPT BioRobotics is expected to post earnings of -$0.39 per share on revenue of $100.84 million. In the same quarter a year earlier PROCEPT BioRobotics reported -$0.38 per share on revenue of $83.33 million. PROCEPT BioRobotics last reported on August 4, 2026, posting -$0.47 per share and missing the -$0.46 consensus estimate. PROCEPT BioRobotics has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.39
Expected Revenue
$100.84 million
Prior-Year EPS
-$0.38
Prior-Year Revenue
$83.33 million
Expected Revenue Growth
+21.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.47 (Missed by -$0.01)
Last Quarter Revenue
$94.50 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

PROCEPT BioRobotics Q3 2026 Earnings FAQ

PROCEPT BioRobotics (NASDAQ:PRCT) is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes.

PROCEPT BioRobotics' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect PROCEPT BioRobotics to post earnings of -$0.39 per share for Q3 2026.

The consensus revenue estimate for PROCEPT BioRobotics is $100.84 million for Q3 2026.

PROCEPT BioRobotics Earnings Headlines

PROCEPT BioRobotics (PRCT) Could Be 70% Undervalued On Lawsuit And Board Change
October 8 at 6:00 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/procept-biorobotics-prct-could-70-151400154.html
Barclays initiates coverage of PROCEPT BioRobotics with overweight rating
October 7 at 6:15 PM  |  msn.comhttps://www.msn.com/en-us/news/other/barclays-initiates-coverage-of-procept-biorobotics-with-overweight-rating/ar-AA2dLJvN
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
October 9 at 1:00 AM  |  Weiss Ratings (Ad)
Barclays Initiates PROCEPT BioRobotics at Overweight With $30 Price Target
October 7 at 1:14 PM  |  marketscreener.comM
Does New Director and Discounting Lawsuit Change The Bull Case For PROCEPT BioRobotics (PRCT)?
October 6 at 3:00 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/does-director-discounting-lawsuit-change-170748934.html
PROCEPT BioRobotics (NASDAQ: PRCT) Investors: Securities Class Action Filed; Shareholders Should Contact Shareholders Foundation
October 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/procept-biorobotics-nasdaq-prct-investors-securities-class-action-filed-shareholders-should-contact-shareholders-foundation-302895650.html
See More PROCEPT BioRobotics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PROCEPT BioRobotics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PROCEPT BioRobotics and other key companies, straight to your email.

About PROCEPT BioRobotics

PROCEPT BioRobotics (NASDAQ:PRCT) Corp. is a medical technology company focused on developing and commercializing robotic and image-guided systems for urologic procedures. The company’s primary focus is benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms.

PROCEPT’s flagship technology is Aquablation therapy, a minimally invasive, robotically controlled treatment that uses a high-velocity waterjet to remove prostate tissue. The therapy is delivered through the company’s AquaBeam Robotic System, which combines real-time imaging, surgical planning and robotic control to assist physicians during prostate procedures. PROCEPT has also developed the HYDROS Robotic System, an advanced platform designed to support Aquablation procedures.

Founded in 2007 and headquartered in Redwood Shores, California, PROCEPT BioRobotics markets its systems primarily through hospitals and urology practices. The company serves the United States and international markets, subject to applicable regulatory clearances and commercial availability. Its common stock trades on the Nasdaq under the symbol PRCT.

View PROCEPT BioRobotics Profile
Earnings Tools